What Is the Wolverine Peptide Stack?
"Wolverine" is a marketing nickname for BPC-157 combined with TB-500, named after the comic-book character who heals fast. It's sold either as one pre-mixed blend vial or as two separate vials. Searches for it have more than doubled this year.
Two things to know up front:
- Neither peptide is FDA-approved for any use. In July 2026, an FDA advisory committee narrowly voted to recommend that BPC-157 and TB-500 be allowed in pharmacy compounding. That's a recommendation, not an approval, and FDA still has to act on it.
- Human evidence is very thin. Most of what you read about "healing" comes from animal studies.
This guide explains what's in the blend and how the math works. It doesn't recommend a dose. Talk with a licensed clinician about whether any of this is appropriate for you.
What's in It
| Component | What it is | What research mostly looks at |
|---|
| BPC-157 | A synthetic 15-amino-acid peptide originally isolated from gastric juice | Tendon, muscle, gut and blood-vessel repair, mostly in rats |
| TB-500 | A synthetic peptide marketed as related to thymosin beta-4 (Tβ4), a naturally occurring repair peptide | Cell migration, wound healing and tissue repair (Tβ4 research) |
One caution on TB-500: much of the research people quote is about thymosin beta-4 itself, not the exact synthetic product sold as "TB-500." They aren't automatically interchangeable.
Wolverine Blend Math: mg per 10 Units
For a blend, every draw contains both peptides in the label's fixed ratio. You can't take more of one without taking more of the other. The math (U-100 syringe, where 10 units = 0.1 mL):
mg of each peptide per 10 units = (mg of that peptide in the vial ÷ mL of water) × 0.1
| Vial label | Water | BPC-157 per 10 units | TB-500 per 10 units |
|---|
| 5 mg + 5 mg | 2 mL | 0.25 mg (250 mcg) | 0.25 mg (250 mcg) |
| 5 mg + 5 mg | 3 mL | 0.167 mg (167 mcg) | 0.167 mg (167 mcg) |
| 10 mg + 10 mg | 2 mL | 0.5 mg (500 mcg) | 0.5 mg (500 mcg) |
| 10 mg + 10 mg | 3 mL | 0.333 mg (333 mcg) | 0.333 mg (333 mcg) |
This is arithmetic, not a dosing schedule. Labels vary by seller, so always use your own vial's label. Run your numbers with the BPC-157 + TB-500 blend calculator.
Wolverine vs GLOW vs KLOW
The three popular "recovery" blends build on each other:
| Blend | BPC-157 | TB-500 | GHK-Cu | KPV |
|---|
| Wolverine | ✓ | ✓ | | |
| GLOW | ✓ | ✓ | ✓ | |
| KLOW | ✓ | ✓ | ✓ | ✓ |
GHK-Cu is a copper peptide that's best known from skin and wound research. KPV is a small peptide studied for inflammation, mostly in cell and mouse models of colitis. More components mean more variables and more unknowns, not proven extra benefit. See our GLOW guide and KLOW guide.
What Human Evidence Exists?
Honestly, very little:
- A 2025 University of Utah review found only three pilot studies of BPC-157 in humans (knee pain, interstitial cystitis and IV safety). No adverse effects were reported, but the authors stressed that "rigorous, large-scale trials are lacking."
- The knee pain study was a retrospective chart review of 16 patients at one clinic. Four of them got BPC-157 plus thymosin beta-4, and 3 of those 4 reported relief. There was no control group and no standardized outcome measure.
- A 2025 IV safety pilot gave BPC-157 to two adults and saw no changes in the blood tests measured.
- A 2026 scoping review from UCLA orthopaedic surgeons found that 67% of publications on these peptides were animal studies, and human data showed "modest improvements at best."
Rat data can be impressive, but they don't tell you whether something works or is safe in people at the amounts sold online.
Regulatory Status
- FDA advisory vote (July 2026): the Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 and TB-500 (along with KPV) to the list of substances 503A pharmacies can compound. It did not find them safe or effective, and FDA rulemaking is still required. Our post-PCAC explainer covers what this means.
- FDA's stated concerns: FDA has published concerns about compounded BPC-157, including possible immune reactions (immunogenicity) and limited safety data.
- "Research use only" vials sold online aren't legal drugs for human use. FDA's 2026 warning letters say that label doesn't change things when the seller is clearly marketing for human use.
- Athletes: if you're drug-tested, check your sport's rules before using any peptide.
Track Recovery Honestly
If you and your clinician decide on a protocol, tracking is how you find out whether anything is actually changing:
- Injury log: a pain score from 0 to 10, range of motion, and what you can and can't do
- Injection sites and rotation, plus any redness or lumps
- Everything else that changed: physical therapy, rest, training load and sleep (these drive most recovery)
PeptIQ puts blend vials, injection-site rotation and weekly check-ins on one timeline. Related: BPC-157 + TB-500 stacking guide, how to mix BPC-157 and TB-500, Wolverine blend profile.
Frequently Asked Questions
Q: What is the Wolverine peptide?
A: A nickname for a BPC-157 + TB-500 combination, sold as one blend vial or two separate vials.
Q: What's the Wolverine peptide dosage per day?
A: There's no clinically established dose. Neither peptide is approved, and human studies are tiny. Online "per day" charts are community protocols, not evidence. A licensed clinician should make any dosing decision.
Q: Wolverine vs KLOW: what's the difference?
A: KLOW adds GHK-Cu and KPV to the BPC-157 + TB-500 base. GLOW adds only GHK-Cu.
Q: Is the Wolverine stack legal?
A: Neither peptide is FDA-approved. An FDA advisory committee recommended in 2026 that they be allowed in pharmacy compounding, but FDA still has to act. "Research use only" vials aren't legal for human use.
Q: Can I adjust the ratio in a blend?
A: No. Every draw has the label's fixed ratio. That's the main tradeoff of a blend compared with separate vials.
Sources
- McGuire FP et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med, 2025
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 2021
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 2025
- Tewari K et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med, 2026
- Goldstein AL et al. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther, 2012
- PharmExec: FDA panel votes to loosen restrictions for four peptides (July 2026 PCAC)
- FDA: July 23-24, 2026 PCAC meeting questions
- FDA: bulk drug substances that may present significant safety risks (BPC-157, KPV, injectable GHK-Cu)
- FDA warning letter: Peak Performance Peptides, Aug 24, 2026 ("research use only" labeling)
This article is educational content from PeptIQ. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.
